Core Viewpoint - The article discusses the health implications and preventive measures associated with the "Xiaoman" solar term in traditional Chinese medicine, emphasizing the importance of diet and lifestyle adjustments during this period to mitigate health issues caused by rising temperatures and humidity [1][2]. Group 1: Health Implications - The Xiaoman period marks the onset of summer climate in China, characterized by increased temperatures and abundant rainfall, which can lead to health issues such as reduced appetite and irritability [1]. - The climate during Xiaoman can cause "damp-heat" in the body, leading to digestive symptoms like reduced appetite and abdominal fullness, as well as emotional disturbances such as irritability and insomnia [1][2]. Group 2: Dietary Recommendations - It is advised to consume light and moisture-reducing foods, such as barley and adzuki beans, while avoiding excessive intake of cold and greasy foods to protect the spleen [1]. - Staying in damp environments should be avoided, and outdoor activities should be limited during peak heat hours [1]. Group 3: Lifestyle Adjustments - Gentle exercises like Tai Chi and Ba Duan Jin are recommended to maintain health, while avoiding intense workouts that may lead to excessive sweating [1]. - Emotional well-being is emphasized, with recommendations to maintain a calm mindset and monitor blood pressure and heart rate, especially for the elderly and those with cardiovascular conditions [2]. Group 4: Traditional Chinese Medicine Practices - External treatments such as gua sha, cupping, and moxibustion on specific acupuncture points are suggested to enhance health and prevent common ailments during this season [2].

Core Viewpoint - The article highlights a community health initiative led by a local medical team in Shaya County, aimed at promoting traditional Chinese medicine (TCM) and enhancing public health awareness among grassroots populations [1][3][4] Group 1: Event Overview - A free medical consultation event titled "Traditional Chinese Medicine Regulations Entering Thousands of Homes" was conducted in a bustling local bazaar, demonstrating the commitment of local representatives to serve the community [1][3] - The event attracted a large number of attendees seeking consultations and experiences with TCM treatments, showcasing the public's interest in traditional health practices [3] Group 2: Medical Services Provided - The medical team utilized traditional diagnostic methods such as pulse diagnosis and the "four examinations" (observation, listening, inquiry, and palpation) to assess patients' conditions [3] - Health professionals provided blood pressure and blood sugar measurements, along with distributing informative brochures on TCM, disease prevention, and health maintenance [3] Group 3: Community Engagement and Impact - The initiative reflects the "people-centered" development philosophy and aims to enhance health services accessibility, effectively bridging the gap in healthcare delivery [3][4] - The event also served to strengthen the relationship between local representatives and the community, emphasizing their role in addressing health needs [3][4] Group 4: Future Plans - The local representative expressed a commitment to continue addressing the health needs of grassroots populations and to promote the expansion of quality medical resources [4] - Shaya County plans to regularly conduct similar public health activities to deepen community engagement and improve health security networks [4]

当现代 技术重构传统炮制工艺、 标准化和便捷性的中药治疗需求持续增长后，中药饮片行业 正经历 从 "经验传承"到"科学验证"的质变 ， 这也推动了行业资本化时刻的到来。 作为国内最全面的中药饮片商之一 ， 四川新荷花中药饮片股份有限公司 （ 下称 " 新荷花 "） 已于 近期向港交所递交上市申请，其可 提供超过 770 种的品种、 4900 个规格的中药饮片，几乎涵盖了 中药行业所使用的主要药物。 由于当前港股市场暂无主营全品类中药饮片的公司上市，新荷花若成功登陆港股，有望成为 "港交所 中药饮片第一股"。这 不仅是一家中药 饮片 企业的资本化进程，更 是 中医药现代化转型的鲜活样 本。 作为中国第二大中药饮片供应商， 新荷花以 "核心中药市场的领导地位 + 面向现代消费者的颠覆性 创新"双支柱战略，构建起传统与现代交融的产业生态 ， 成为中药饮片现代化进程的重要脚注。 紧握 市场 变革的脉络 新荷花能够稳坐中药饮片龙头的地位，正是因为其始终紧握 市场 变革的 四大脉络：集采的 "优质优 价"、细分渠道、行业专业化、健康管理需求变迁。 变革一： 近年来， 政策端 对中医药产业的扶持力度持续加码，为中药饮片的标 ...

如今，每年入夏，这里都会变身白色花海。正在采摘新鲜栀子花的当地民众邹南金告诉记者，以往 每到这个季节，他都会到菜市场买栀子花炒着吃。"很美、很香，今天跟朋友第一次来这里采摘栀子 花，非常开心。" 几位身着汉服的游客漫步花间打卡拍照，花田音乐会、药膳DIY、花田童趣、骑行花海等丰富活 动，吸引各地游客畅游花海，参与其中。 樟树素有"药不到樟树不齐，药不过樟树不灵"的美誉，作为中国国家地理标志产品，黄栀子是樟树 道地药材"三子一壳"之一，广泛用于色素提炼、食品、医药等领域，经济价值较高。 地处平原与丘陵过渡带的义成镇历史上是赣中地区农业重镇，气候湿润、土壤肥沃，适合中药材种 植。过去有大量农户从事药材散种，但规模不大、品种繁多，在选材、用药等方面缺乏统一标准，不仅 给管理带来挑战，也不利于中药材品质提升。 从2000年开始，当地种植大户刘细流开始在此开拓荒山种植黄栀子，一坚持就是25年。"刚开始的 时候，这里几乎是一片荒山，电都不通。伴随着政策的东风，我们种植规模逐渐提升到了如今的5000余 亩，也从以往的散户模式，走上规模化、产业化之路。" 初夏时节，位于中国药都江西樟树市义成镇罗港村的5000亩栀子花盛放，白 ...

Group 1 - The 78th World Health Assembly will open on May 19, with China's delegation actively participating and sharing its contributions to global health governance [1][2] - China is committed to supporting the World Health Organization (WHO) in its central coordinating role in global health governance and aims to enhance the health interests of developing countries [1] - The assembly will review the draft of the "Pandemic Accord," which is of significant interest, and China will support WHO's leadership in global public health governance [1] Group 2 - China is integrating traditional medicine into its health system and promoting the fusion of traditional and modern medicine, collaborating with over 40 countries and regions [2] - The theme of the general debate at the World Health Assembly is "Creating a Healthy World," and China will host side events to share its experiences [2]

活动现场，专家团队正在为侨胞进行健康问诊。人民网记者 宋亦然摄 "本次义诊不仅展示了中医药'简、便、验、廉'的特色优势，也为增进巴西侨胞对中医文化的了解 搭建了平台。海外华侨华人长期以来对中医有着浓厚兴趣和深厚信任，此次四川专家的到来，为广大侨 胞带来了实实在在的健康福音。"巴西中国和平统一促进会会长张小春在致辞中说。 四川海外联谊会副会长黄永明发表致辞。人民网记者 宋亦然摄 中国驻里约热内卢总领馆副总领事王尉育发表致辞。人民网记者 宋亦然摄 中国驻里约热内卢总领馆副总领事王尉育在致辞中表示，中医文化博大精深，是中华优秀传统文化 的重要代表，深受海外侨胞喜爱。此次四川中医专家远道而来，体现了对侨胞的深切关怀。他希望侨胞 继续发挥"以侨为桥"的作用，积极向当地社会传播中医文化，让更多巴西民众了解中国、亲近中国。 人民网里约热内卢5月17日电（记者陈一鸣、宋亦然）一位年长侨胞卷起衣袖，露出常年酸痛的肩 膀，四川省中西医结合医院针灸中心副主任郭子衣指尖轻点穴位，入针沉稳，针身轻颤，接受治疗的侨 胞瞬间眉头舒展："肩头一下子松快多了！"不远处，四川省骨科医院天府院区颈肩腰腿痛科副主任医师 吴忌正熟练地为患者推拿调理， ...

波兰TOMO中医学院名誉院长、经典中医学术顾问李颉分享了海外民众对中医的需求特点。他表 示，在疾病预防、复杂性疾病治疗等领域，中医具有显著优势。据他观察，针灸和中药在国外的认可度 日益提升，外籍中医师队伍也在不断壮大。"此次带领国外学生参会，目的是让他们深入感受中医的核 心文化内涵，加深对中医的理解与感悟。" 据悉，国医新路论坛已举办三届，是由王新陆牵头创办的公益性中医学术论坛，由国医新路论坛秘 书处、李克绍伤寒学派传承基地主办，山东新中鲁中医医院承办。（周艺伟） "《伤寒论》作为中医四大经典之一，在中医学中占据至关重要的地位，素有'活人书'之称。"李克 绍伤寒学派传承人、山东新中鲁中医医院院长李树沛说，作为本次论坛的承办单位，山东新中鲁中医医 院始终以《伤寒论》等中医经典为临床指导，将传统智慧与现代诊疗相结合，致力于用纯正的中医经典 理论与方法为患者解除病痛。 "当代伤寒流派高峰论坛"暨第三届国医新路学术论坛17日在山东济南举行。来自中国、波兰、荷兰 等国家的400余位中医专家学者齐聚泉城，共同探讨伤寒流派传承发展，推动中医药文化国际交流。 国医大师、中国中医科学院学部委员王新陆接受记者采访时表示，中医源于 ...

Group 1 - The core of the collaboration between Chunyu Doctor and Zhongke Wenge focuses on integrating AI technology with traditional Chinese medicine, specifically through the development of a large model that utilizes clinical data and diagnostic cases related to tongue diagnosis [2][4] - Chunyu Doctor, founded in 2011, has become a leader in China's mobile internet healthcare sector, accumulating 1.8 billion users and over 68,000 practicing physicians on its platform by March 2025 [3] - The daily consultation volume for Chunyu Doctor exceeds 390,000, with a customer satisfaction rate of 98%, indicating its effectiveness as a comprehensive digital healthcare platform [5] Group 2 - Zhongke Wenge, an AI enterprise incubated by the Chinese Academy of Sciences, focuses on decision intelligence technology and has developed proprietary systems for AI data operations and multi-modal models [6] - The strategic partnership aims to create an integrated AI service system for traditional Chinese medicine that encompasses prevention, diagnosis, treatment, and health management [4]

Core Viewpoint - The company, Panlong Pharmaceutical, has demonstrated steady growth in its operations and profitability in 2024, with significant advancements in its product offerings and market position in the field of rheumatology and bone injuries [1][4][12]. Group 1: Company Performance - In 2024, Panlong Pharmaceutical achieved a revenue of 974 million yuan, remaining stable compared to the previous year, with a 10.20% year-on-year growth in self-produced traditional Chinese medicine (TCM) business [4][5]. - The company reported a net profit of 120 million yuan in 2024, marking an 8.91% increase year-on-year, continuing its profit growth for eight consecutive years since its listing [5][8]. - The gross profit margin for the company improved to 60.82%, an increase of nearly 2.9 percentage points from the previous year [5]. Group 2: Product Development and Market Position - The flagship product, Panlong Seven, holds the largest market share in the TCM market for musculoskeletal and rheumatic diseases, with a market share of 8.05% [3][4]. - The company has expanded its product matrix, achieving a three-digit growth rate in its subsidiary, Panlong Plant Medicine, and has registered 211 varieties of formula granules, marking a significant breakthrough [1][4]. Group 3: Innovation and R&D - In 2024, the company increased its R&D investment to 37.54 million yuan, representing an 85.31% increase from 2023, which is 5.05% of its self-produced TCM revenue [9][10]. - The company has established multiple research platforms and is actively developing innovative TCM products, with a focus on high-quality manufacturing and digital transformation [9][10]. Group 4: Marketing and Distribution - Panlong Pharmaceutical has built a comprehensive marketing network across 30 provinces in China, collaborating with over 630 pharmaceutical companies to distribute its products to more than 4,800 hospitals and 7,000 pharmacies [11]. - The company is also embracing e-commerce by launching official flagship stores on platforms like Tmall and JD, enhancing its market reach [11]. Group 5: Industry Outlook - The TCM industry is experiencing a golden period driven by policy, demand, and technology, with Panlong Pharmaceutical positioned to benefit from these trends [12][13]. - The company's strategic vision focuses on becoming a leader in rheumatology and pain management, aiming for high-quality development and increased operational efficiency [13].

Group 1 - The core viewpoint of the news is the successful re-election of the Microcirculation Medication Professional Committee of the China Traditional Chinese Medicine Association, which aims to enhance the development and application of microcirculation in traditional Chinese medicine [1][5] - The second term work plan includes four main areas: promoting collaborative innovation, deepening research and application of traditional Chinese medicine, academic dissemination and brand building, and policy research and industry standards [1][8] - The new committee consists of 215 members, with Professor Wang Xiaolong elected as the new chairman and 32 vice-chairmen elected from various institutions [7] Group 2 - The first committee's work was summarized, highlighting the close relationship between microcirculation and various diseases, and the need for interdisciplinary collaboration [3] - The newly elected committee's management regulations were announced, clarifying its nature, business scope, member management, organizational structure, and financial management [7] - The emphasis on the importance of microcirculation research in the inheritance and innovation of traditional Chinese medicine was reiterated, along with expectations for the new committee to focus on disease prevention and treatment challenges [8]